Skip to main content

Advertisement

Table 1 Baseline characteristics and medication at baseline and during follow up in 166 patients with ankylosing spondylitis

From: A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis

  Total group Men (n = 89) Women (n = 77) p value
Demographic variables
 Age, years 50 (13) 49 (12) 51 (13) 0.45
 Current smokers 17 (10) 8 (9) 9 (12) 0.75
 Ever-smokers 72 (43) 41 (46) 31 (40) 0.55
 BMI category: normal/overweight/obese 85 (51)/ 41 (46)/ 44 (57)/ 0.36
56 (34)/ 33 (37)/ 23 (30)/
25 (15) 15 (17) 10 (13)
 Blue-collar workera 40 (33) 21 (33) 19 (33) 1.00
 Time between x-rays, months 66 (3) 65 (3) 67 (1) 0.003
Disease-related variables
 Duration of symptoms, years 24 (13) 23 (13) 24 (13) 0.58
 History of anterior uveitis 85 (51) 50 (56) 35 (46) 0.22
 History of peripheral arthritis 95 (57) 47 (53) 48 (62) 0.28
 History of coxitis 13 (8) 7 (8) 6 (8) 1.00
 BASMI, score 3.0 (1.5) 3.2 (1.8) 2.9 (1.2) 0.61
 BASFI, score 2.5 (2.0) 2.3 (1.9) 2.7 (2.1) 0.25
 BASDAI, score 3.4 (2.1) 3.1 (2.1) 3.7 (2.0) 0.056
 ASDAS_CRP, score 2.1 (0.9) 2.1 (0.9) 2.1 (0.8) 0.53
 CRP, mg/L 5.4 (8.5) 6.5 (10.5) 4.2 (5.1) 0.26
 Time-averaged CRP during follow up, mg/L 5.8 (5.9) 6.5 (6.4) 4.9 (5.0) 0.043
ESR, mm/h 14.2 (11.2) 12.7 (11.5) 15.9 (10.6) 0.003
 Time-averaged ESR during follow-up, mm/h 12.2 (8.4) 10.9 (7.8) 13.8 (8.9) 0.009
 HLA-B27 positive 143 (86) 82 (92) 61 (79) 0.030
 Aortic insufficiencyb 25 (16) 13 (16) 12 (17) 0.98
 mSASSS, score 13.9 (18.6) 20.3 (21.9) 6.4 (9.6) < 0.001
 Presence of syndesmophyte 76 (46) 51 (57) 25 (33) 0.002
Medications
 Patients on NSAIDs baseline 129 (78) 66 (74) 63 (82) 0.32
 NSAID index during follow up, 0–100 34 (38) 39 (39) 29 (33) 0.31
 Patients on TNFi at baseline 33 (20) 22 (25) 11 (14) 0.14
 Patients exposed to TNFi during follow up 49 (30) 30 (34) 19 (25) 0.27
 Patients on bisphosphonate at baseline 7 (4) 1 (1) 6 (8) 0.050
 Patients exposed to bisphosphonate during follow-up 30 (18) 11 (12) 19 (25) 0.064
  1. Values are means (SD) or numbers of patients (%)
  2. ASDAS_CRP Ankylosing Spondylitis Disease Activity Score_C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HLA-B27 human leukocyte antigen B27, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, NSAID non-steroidal anti-inflammatory drug, TNFi tumor necrosis factor inhibitor
  3. an = 120 for total group, 63 men and 57 women
  4. bn = 153 for total group, 83 men and 70 women